Payment overview · 2025
General Payments
$1,403.17
71 reported records · 17 companies
Healthcare provider profile · identity verified
Abdulhadi Sinan, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · DEARBORN, MI · NPI 1841242245
Verified facts
What the public records show
CMS Open Payments records show Abdulhadi Sinan, M.D. received $1,403.17 in general payments during 2025 across 71 reported records.
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) accounted for 19.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 22 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance, Mounjaro, Ozempic, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 144 claims for Linzess by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 102 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 253 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 121 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 253 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 117 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 116 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $266.84 | 19.0% | 14 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $220.64 | 15.7% | 12 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $192.14 | 13.7% | 5 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $129.33 | 9.2% | 6 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $116.36 | 8.3% | 7 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $84.32 | 6.0% | 5 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $83.55 | 6.0% | 5 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $50.46 | 3.6% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $50.37 | 3.6% | 2 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $47.18 | 3.4% | 3 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $34.12 | 2.4% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $28.95 | 2.1% | 2 | 2025 |
| Cipher Pharmaceuticals US LLC | Unresolved — no canonical attribution shown | $26.87 | 1.9% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $23.29 | 1.7% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $20.25 | 1.4% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $14.72 | 1.1% | 1 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $13.78 | 1.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,403.17 | 71 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $266.84 | 14 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $192.14 | 5 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $129.33 | 6 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $116.36 | 7 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $99.36 | 6 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $84.32 | 5 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $69.89 | 4 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $68.55 | 4 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $50.46 | 3 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $50.37 | 2 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $47.18 | 3 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $46.68 | 3 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $34.12 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $28.95 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $28.95 | 2 | 2025 |
Source payment records
|
|||||
| Natroba Normalized: natroba |
Drug | Cipher Pharmaceuticals US LLC | $26.87 | 1 | 2025 |
Source payment records
|
|||||
| Spinosad Normalized: spinosad |
Drug | Cipher Pharmaceuticals US LLC | $26.87 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $23.29 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $20.25 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $14.72 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $14.69 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $14.43 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 116 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 253 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 33 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 117 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 121 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
144 | 36 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
102 | 26 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
253 | 46 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
121 | 27 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
253 | 46 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
117 | 21 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
116 | 28 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 797 | 148 |
| Metformin Hcl | Metformin Hcl | 641 | 123 |
| Amlodipine Besylate | Amlodipine Besylate | 623 | 127 |
| Omeprazole | Omeprazole | 471 | 92 |
| Lisinopril | Lisinopril | 464 | 97 |
| Metoprolol Succinate | Metoprolol Succinate | 462 | 87 |
| Levothyroxine Sodium | Levothyroxine Sodium | 315 | 58 |
| Losartan Potassium | Losartan Potassium | 271 | 52 |
| Fluticasone Propionate | Fluticasone Propionate | 258 | 66 |
| Jardiance | Empagliflozin | 253 | 46 |
| Famotidine | Famotidine | 250 | 61 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 241 | 64 |
| Tamsulosin Hcl | Tamsulosin Hcl | 210 | 51 |
| Carvedilol | Carvedilol | 206 | 43 |
| Hydrochlorothiazide | Hydrochlorothiazide | 205 | 54 |
| Pantoprazole Sodium | Pantoprazole Sodium | 200 | 42 |
| Meloxicam | Meloxicam | 182 | 57 |
| Simvastatin | Simvastatin | 175 | 32 |
| Clopidogrel | Clopidogrel Bisulfate | 174 | 33 |
| Januvia | Sitagliptin Phosphate | 168 | 27 |
| Alendronate Sodium | Alendronate Sodium | 156 | 25 |
| Nifedipine Er | Nifedipine | 155 | 29 |
| Glipizide Er | Glipizide | 145 | 26 |
| Linzess | Linaclotide | 144 | 36 |
| Celecoxib | Celecoxib | 143 | 45 |
| Gabapentin | Gabapentin | 138 | 37 |
| Glipizide | Glipizide | 131 | 21 |
| Duloxetine Hcl | Duloxetine Hcl | 129 | 30 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 121 | 27 |
| Furosemide | Furosemide | 117 | 29 |
| Hydralazine Hcl | Hydralazine Hcl | 117 | 24 |
| Ozempic | Semaglutide | 117 | 21 |
| Eliquis | Apixaban | 116 | 28 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 114 | 25 |
| Metoprolol Tartrate | Metoprolol Tartrate | 111 | 26 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 107 | 36 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 105 | 50 |
| Farxiga | Dapagliflozin Propanediol | 102 | 26 |
| Citalopram Hbr | Citalopram Hydrobromide | 98 | 26 |
| Diclofenac Sodium | Diclofenac Sodium | 98 | 41 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 98 | 21 |
| Tizanidine Hcl | Tizanidine Hcl | 96 | 44 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 95 | 23 |
| Montelukast Sodium | Montelukast Sodium | 94 | 20 |
| Ventolin Hfa | Albuterol Sulfate | 89 | 21 |
| Ibuprofen | Ibuprofen | 83 | 31 |
| Naproxen | Naproxen | 82 | 37 |
| Promethazine Hcl | Promethazine Hcl | 79 | 43 |
| Allopurinol | Allopurinol | 77 | 12 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 76 | 12 |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 73 | 21 |
| Myrbetriq | Mirabegron | 73 | 12 |
| Azithromycin | Azithromycin | 71 | 50 |
| Tradjenta | Linagliptin | 70 | 11 |
| Alprazolam | Alprazolam | 68 | 15 |
| Entresto | Sacubitril/Valsartan | 66 | 11 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 62 | 15 |
| Tramadol Hcl | Tramadol Hcl | 62 | 27 |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 60 | 21 |
| Glimepiride | Glimepiride | 60 | 11 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 59 | 16 |
| Escitalopram Oxalate | Escitalopram Oxalate | 57 | 15 |
| Pregabalin | Pregabalin | 57 | 12 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 53 | 19 |
| Trazodone Hcl | Trazodone Hcl | 52 | 13 |
| Donepezil Hcl | Donepezil Hcl | 50 | 12 |
| Pravastatin Sodium | Pravastatin Sodium | 50 | 12 |
| Sertraline Hcl | Sertraline Hcl | 50 | 11 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 46 | 13 |
| Clonazepam | Clonazepam | 45 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 45 | 11 |
| Metoclopramide Hcl | Metoclopramide Hcl | 45 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 45 | 16 |
| Atenolol | Atenolol | 43 | suppressed |
| Mupirocin | Mupirocin | 43 | 31 |
| Ropinirole Hcl | Ropinirole Hcl | 43 | suppressed |
| Baclofen | Baclofen | 42 | suppressed |
| Prednisone | Prednisone | 42 | 19 |
| Amitriptyline Hcl | Amitriptyline Hcl | 41 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 39 | 12 |
| Meclizine Hcl | Meclizine Hcl | 39 | 17 |
| Finasteride | Finasteride | 38 | 13 |
| Potassium Chloride | Potassium Chloride | 38 | 12 |
| Warfarin Sodium | Warfarin Sodium | 37 | suppressed |
| Xarelto | Rivaroxaban | 36 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 35 | suppressed |
| Spironolactone | Spironolactone | 35 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 35 | 28 |
| Brilinta | Ticagrelor | 34 | suppressed |
| Cephalexin | Cephalexin | 34 | 26 |
| Calcitriol | Calcitriol | 33 | suppressed |
| Mounjaro | Tirzepatide | 33 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 31 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 28 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 28 | suppressed |
| Trulicity | Dulaglutide | 27 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 27 | suppressed |
| Ezetimibe | Ezetimibe | 25 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 25 | suppressed |
| Lidocaine | Lidocaine | 25 | suppressed |
| Topiramate | Topiramate | 25 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 24 | suppressed |
| Clotrimazole | Clotrimazole | 24 | 16 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 24 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 22 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 21 | 16 |
| Midodrine Hcl | Midodrine Hcl | 21 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 20 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 20 | suppressed |
| Nitroglycerin | Nitroglycerin | 20 | suppressed |
| Torsemide | Torsemide | 20 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 19 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 19 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 18 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 18 | suppressed |
| Hydrocortisone | Hydrocortisone | 18 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 18 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 18 | suppressed |
| Loperamide | Loperamide Hcl | 17 | suppressed |
| Lorazepam | Lorazepam | 17 | suppressed |
| Memantine Hcl | Memantine Hcl | 17 | suppressed |
| Mirtazapine | Mirtazapine | 17 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 16 | suppressed |
| Methocarbamol | Methocarbamol | 16 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 16 | suppressed |
| Alcohol Swabs | Alcohol Antiseptic Pads | 15 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 15 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 14 | suppressed |
| Bumetanide | Bumetanide | 14 | suppressed |
| Clonidine | Clonidine | 14 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 14 | suppressed |
| Methylprednisolone | Methylprednisolone | 14 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 14 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 14 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 13 | 12 |
| Bupropion Hcl | Bupropion Hcl | 13 | suppressed |
| Bupropion Xl | Bupropion Hcl | 13 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 13 | suppressed |
| Eplerenone | Eplerenone | 13 | suppressed |
| Lactulose | Lactulose | 13 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 13 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 13 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 12 | suppressed |
| Insulin Syringe | Syringe-Needle,insulin,0.5 Ml | 12 | suppressed |
| Ropinirole Er | Ropinirole Hcl | 12 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 11 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 11 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 11 | suppressed |
| Methimazole | Methimazole | 11 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 11 | suppressed |
| Risperidone | Risperidone | 11 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 11 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,403.17 · 71 records | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | AIRSUPRA, Auvelity, CAPLYTA, Cologuard Collection Kit, ELIQUIS, IBSRELA, JARDIANCE, MOUNJARO, NURTEC ODT, Natroba, OTEZLA, Ozempic, REPATHA, REXULTI, Spinosad, TRELEGY ELLIPTA, VOQUEZNA, VRAYLAR, Wegovy, XIFAXAN, ZAVZPRET, ZEPBOUND | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error